MDX-210

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameMDX-210

Drug Alias NameAnti-ovary-cancer-TriggerAnti-breast-cancer-TriggerTriggerMDX-210

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionHigh affinity immunoglobulin gamma Fc receptor I antagonistsReceptor protein-tyrosine kinase erbB-2 antagonists

TargetsReceptor protein-tyrosine kinase erbB-2High affinity immunoglobulin gamma Fc receptor I

Therapy Area/IndicationsProstatic NeoplasmsColorectal NeoplasmsBreast Neoplasms +[4]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesTakeda Pharmaceutical Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesTakeda Pharmaceutical Co Ltd

Active IndicationsN/A

Inactive IndicationsProstatic NeoplasmsColorectal NeoplasmsBreast Neoplasms +[4]

Other Information

ATC CodeN/A